Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies

Willegaignon, José; Pelissoni, Rogério Alexandre; Lima, Beatriz C.G.D.; Sapienza, Marcelo Tatit; Filho, George Coura; Buchpiguel, Carlos Alberto

doi:10.1097/mnm.0000000000000465

Cited by 7 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding reproducibility, it is difficult to state that the pharmacokinetic behavior observed in the therapy will be the same as that in the diagnostic study performed with “tracer” activities, since the physiological conditions of the organism can vary between two moments (e.g., TSH level in radioiodine therapy, renal function, and hydration) 45. In cases where internal dosimetry is performed to establish the dose resulting from the therapeutic cycle itself, with high activity and low noise in the images, dosimetric data are useful for the eventual planning of subsequent therapeutic cycles.…”

Section: Introductionmentioning

confidence: 99%

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

Sapienza¹,

Willegaignon²

2019

Clinics

Self Cite

View full text Add to dashboard Cite

The efficacy and toxicity of radionuclide therapy are believed to be directly related to the radiation doses received by target tissues; however, nuclear medicine therapy continues to be based primarily on the administration of empirical activities to patients and less frequently on the use of internal dosimetry for individual therapeutic planning. This review aimed to critically describe the techniques and clinical evidence of dosimetry as a tool for therapeutic planning and the main limitations to its implementation in clinical practice. The present article is a nonsystematic review of voxel-based dosimetry. Clinical evidence pointing to a correlation between the radiation dose and therapeutic response in various diseases, such as thyroid carcinoma, neuroendocrine tumors and prostate cancer, is reviewed. Its limitations include technical aspects related to image acquisition and processing and the lack of randomized clinical trials demonstrating the impact of dosimetry on patient therapy. A more widespread use of dosimetry in therapeutic planning involves the development of user-friendly dosimetric protocols and confirmation that dose estimation implies good efficacy and low treatment-related toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

Sapienza¹,

Willegaignon²

2019

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…From our perspective, several factors in the following may play a partial role in this process. (1) decay of iodine-131 with a half-life of approximately 8.2 days, (2) poor spatial resolution of SPECT imaging compared with fluorescence imaging, and (3) the release of 131 I due to the deiodination of 131 I-Hyp. Dissociation of radioiodine from the ortho position of the phenolic group is called deiodination .…”

Section: Resultsmentioning

confidence: 99%

Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation

Bao,

Wang,

Chen

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Thermal ablation has been commonly used as an effective treatment for hepatocellular carcinoma; however, perinecrotic tumor residues after ablation play a significant role in tumor recurrence and poor prognosis. Therefore, developing agents that can effectively target and eliminate residual tumors is critically needed. Necrosis targeting strategies have potential implications for evaluating tumor necrosis areas and treating the surrounding residual tumors. To address this issue, we have developed a biodegradable nanoparticle with necrosis avidity that is compatible with fluorescence imaging, single photon emission computed tomography (SPECT) imaging, and necrosis targeted radiotherapy. The nanoparticles were synthesized using iodine-131-labeled hypericin ( 131 I-Hyp) as the core and amphiphilic copolymer poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG−PCL) as the shell. The developed nanoparticle, PNP@( 131 I-Hyp), has a uniform spherical morphology with a size of 33.07 ± 3.94 and 45.93 ± 0.58 nm determined by cryogenic transmission electron microscopy (cryo-TEM) and dynamic lightscattering analysis (polydispersity index = 0.19 ± 0.01), respectively, and having a good stability and blood compatibility in vitro. In mouse subcutaneous ablated-residual tumor models, fluorescence and SPECT imaging demonstrated that PNP@( 131 I-Hyp) prominently accumulated in the tumor and was retained for as long as 168 h following intravenous injection. Moreover, ex vivo analyses showed that PNP@( 131 I-Hyp) mainly gathered in the necrotic zones of subcutaneous tumors and inhibited residual tumors by radiotherapy. In addition, histological examination of harvested organs and hematological analysis demonstrated that intravenous injection of 5 mCi/kg nanoparticles caused no gross abnormalities. This multifunctional nanoparticle, therefore, has necrosis imaging and targeted therapeutic effects on residual tumors after thermal ablation of hepatocellular carcinoma, showing potential for clinical application.

show abstract

“…For preparation for RAI therapy, levothyroxine need to be withdrawn, which induce state of hypothyroidism in patients and lead to a reduction in glomerular ltration rate and retention of iodine-131 18 . Consumption of large amounts of liquids is encouraged mainly after one day post-therapy administration to enable the excretion of free iodine-131 from blood circulation, on considering that after this period of time all free iodine-131 will produce only body irradiation without any impact on patient therapy 16 . In our study we found that eGFR is related with effective half-life.…”

Section: Discussionmentioning

confidence: 99%

Estimation of Clearance Rate of Iodine-131 From Thyroid Cancer Patients Based on Individual Patient’s Characteristic.

Myssayev

Ideguchi

et al. 2020

Preprint

View full text Add to dashboard Cite

Differentiated thyroid carcinomas (DTC) are the most frequent malignancies of the endocrine system in 2015 in Japan. The purpose of this study is to estimate clearance rate of Iodine-131 from thyroid cancer patients based on individual patient’s characteristics. Materials and methods: We conducted retrospective study including 87 cases with DTC who had received RAI from June 2016 till July 2018. Patients who had complete information on primary tumor size (PTS) as mentioned in their histopathology reports, TNM staging, serum TSH (uIU/ml), free-T3 (pg/mL), free-T4 (ng/dL), thyroglobulin level (Tg) (ng/ml) (one month before, on the day of the treatment, and one month after receiving RAI), anti-Tg antibodies (IU/mL), dose of Levothyroxine (before and after RAI), as well as renal function (creatinine, BUN, eGFR), exposure rate (µSv/h) and taken dose (mCi) were included in our study. Results: Univariate analysis showed significant associations of effective half-life with several factors (gender, body height, body weight, eGFR, size of tumor, dose of Levothyroxine, free-T3 one month after receiving RAI). Conclusion: Effective management of these factors could help the doctors to optimize the occupancy of isolated rooms with higher output, but also reduce the operational cost of the hospital and improving the comfort to patients.

show abstract

Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies

Cited by 7 publications

References 19 publications

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation

Estimation of Clearance Rate of Iodine-131 From Thyroid Cancer Patients Based on Individual Patient’s Characteristic.

Contact Info

Product

Resources

About